"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome

Oncotarget
Patrizia ViciFilippo Montemurro

Abstract

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identified 872 TP BC pts treated with adjuvant chemotherapy alone (cohort A-366 pts), or plus trastuzumab (cohort B-506 pts). Relapse-free-survival (RFS) and breast-cancer-specific-survival (BCSS) were evaluated. Trastuzumab improved RFS and BCSS in all the subsets analyzed, but the effect on BCSS in tumors expressing both HRs in >30% of cells (TP30), and even on RFS in tumors with both HRs expressed in >50% of cells (TP50) was not significant. Distinct patterns of relapse were observed in TP50 and no-TP50 tumors, the former showing low and constant risk in the first 5 years, a late increase beyond 5 years and modest trastuzumab effect. Trastuzumab effect tended to disappear in pts whose tumors expressed ER in >50% of cells. Multivariate analysis of RFS confirmed a significant interaction between trastuzumab and ER expression, with benefit confined to pts whose tumors expressed ER in ≤50% of cells. Our data suggest that the pattern of relapse...Continue Reading

References

Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T SaphnerR Gray
Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Mar 5, 1999·Breast Cancer Research and Treatment·S G HilsenbeckG M Clark
May 11, 2006·Breast Cancer Research and Treatment·William F AndersonPhilip S Rosenberg
Oct 12, 2007·The New England Journal of Medicine·Daniel F HayesUNKNOWN Cancer and Leukemia Group B (CALGB) Investigators
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Nov 26, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rohit BhargavaGretchen M Ahrendt
Dec 15, 2010·Nature Reviews. Clinical Oncology·Javier CortésMaría Vidal
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Lorenzo MojaRoberto D'Amico
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Dec 12, 2012·Breast Cancer Research and Treatment·Kenneth R Hess, Francisco J Esteva
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezMonica M Reinholz
Jul 23, 2013·Lancet·Aron GoldhirschUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Aug 3, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F MontemurroG Arpino
Nov 23, 2013·Journal of the National Cancer Institute·Katherine L Pogue-GeileSoonmyung Paik
Jan 3, 2015·Cancer Treatment Reviews·Patrizia ViciPaolo Marchetti
Jan 7, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine L Pogue-GeileSoonmyung Paik
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezMonica M Reinholz
Apr 19, 2015·Breast Cancer Research : BCR·Kathrin Strasser-WeipplPaul E Goss

❮ Previous
Next ❯

Citations

Mar 25, 2016·Endocrine-related Cancer·Tanja IgnatovAtanas Ignatov
Feb 20, 2019·Journal of Clinical Medicine·Marco MazzottaPatrizia Vici
Dec 14, 2019·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Iveta KolarovaMartin Dolezel
Jun 27, 2017·Expert Review of Anticancer Therapy·Isabel EchavarriaMiguel Martin
Nov 25, 2016·Expert Review of Anticancer Therapy·Matteo LambertiniEvandro de Azambuja
Sep 26, 2020·Breast Cancer Research and Treatment·Hikmat Abdel-RazeqAyat Taqash
May 13, 2017·International Journal of Oncology·Martina S J McDermottNorma O'Donovan
May 10, 2018·Endocrine-related Cancer·Bin ZhaoJiaxin Zhao
Oct 29, 2020·Archives of Pathology & Laboratory Medicine·Jennifer ZengTimothy M D'Alfonso
Aug 16, 2021·The Breast : Official Journal of the European Society of Mastology·Francesco Schettini, Aleix Prat

❮ Previous
Next ❯

Software Mentioned

SPSS
Software
STEPP
R

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Related Papers

The New England Journal of Medicine
Soonmyung PaikNorman Wolmark
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
Imjai ChitapanaruxPatrinee Traisathit
Annals of Oncology : Official Journal of the European Society for Medical Oncology
H JoensuuM Bates
© 2022 Meta ULC. All rights reserved